TCON vs. TCBP, FRTX, KRBP, NSTGQ, FNCH, PALI, TTNP, ALBT, CELZ, and ELOX
Should you be buying TRACON Pharmaceuticals stock or one of its competitors? The main competitors of TRACON Pharmaceuticals include TC Biopharm (TCBP), Fresh Tracks Therapeutics (FRTX), Kiromic BioPharma (KRBP), NanoString Technologies (NSTGQ), Finch Therapeutics Group (FNCH), Palisade Bio (PALI), Titan Pharmaceuticals (TTNP), Avalon GloboCare (ALBT), Creative Medical Technology (CELZ), and Eloxx Pharmaceuticals (ELOX). These companies are all part of the "biological products, except diagnostic" industry.
TRACON Pharmaceuticals (NASDAQ:TCON) and TC Biopharm (NASDAQ:TCBP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation, dividends and community ranking.
TRACON Pharmaceuticals presently has a consensus price target of $60.00, suggesting a potential upside of 4,095.80%. Given TRACON Pharmaceuticals' higher possible upside, research analysts plainly believe TRACON Pharmaceuticals is more favorable than TC Biopharm.
TRACON Pharmaceuticals has higher revenue and earnings than TC Biopharm.
TC Biopharm's return on equity of 0.00% beat TRACON Pharmaceuticals' return on equity.
TRACON Pharmaceuticals has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, TC Biopharm has a beta of 0.13, meaning that its share price is 87% less volatile than the S&P 500.
TRACON Pharmaceuticals received 265 more outperform votes than TC Biopharm when rated by MarketBeat users. Likewise, 58.46% of users gave TRACON Pharmaceuticals an outperform vote while only 50.00% of users gave TC Biopharm an outperform vote.
11.6% of TRACON Pharmaceuticals shares are owned by institutional investors. Comparatively, 16.3% of TC Biopharm shares are owned by institutional investors. 5.3% of TRACON Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of TC Biopharm shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, TRACON Pharmaceuticals had 6 more articles in the media than TC Biopharm. MarketBeat recorded 8 mentions for TRACON Pharmaceuticals and 2 mentions for TC Biopharm. TC Biopharm's average media sentiment score of 0.54 beat TRACON Pharmaceuticals' score of -0.10 indicating that TC Biopharm is being referred to more favorably in the news media.
Summary
TRACON Pharmaceuticals beats TC Biopharm on 10 of the 14 factors compared between the two stocks.
Get TRACON Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for TCON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TCON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TRACON Pharmaceuticals Competitors List
Related Companies and Tools
